FDA Holds Hearing on Jet Lag Sleep Drug
Published Date: 6/3/2026
Notice
Summary
Vanda Pharmaceuticals asked the FDA to approve a new use for their sleep drug HETLIOZ to treat jet lag, but the FDA said no and now there’s a public hearing to decide what’s next. This affects Vanda, travelers hoping for a jet lag fix, and could delay the drug’s availability while money and time are on the line. The hearing starts July 20, 2026, so mark your calendars!
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11062 — Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
The FDA is officially pulling the plug on 16 generic drug approvals because the companies told them these medicines aren’t being sold anymore. This change kicks in on July 6, 2026, and it won’t stop companies from trying again later if they want. If you’re a drug maker or just curious, this means fewer old approvals cluttering the books and a cleaner, fresher drug list.
2026-11060 — Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities-Questions and Answers; Revised Draft Guidance for Industry; Availability
The FDA just released a revised draft guide to help drug and device makers share important cost and coverage info with insurance companies and similar groups. This update clears up how to talk about approved products, unapproved products, and new uses, making it easier for everyone to understand the rules. Companies should send their feedback by August 3, 2026, so the FDA can finalize the guide—potentially speeding up coverage decisions and saving money.
2026-11054 — Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help companies making gene therapy products that use genome editing. It shows how to use what’s already known to speed up development and get safer, smarter treatments to patients faster. If you’re in this field, send your feedback by September 1, 2026, so your voice shapes the final rules—saving time and money down the road!
2026-11101 — Third Annual Animal Drug User Fee Educational Conference; Public Meeting
The FDA is hosting its Third Annual Animal Drug User Fee Educational Conference on July 7, 2026, to help drug makers and animal health experts understand the new animal drug approval process. This free event is both in-person and online, making it easy to join. Stakeholders should register early and can send feedback within 90 days after the meeting to help shape future policies and fees.
2026-10908 — Medical Devices; General Hospital and Personal Use Devices; Classification of the Rigid Sterilization Container With Electronic Monitoring
The FDA is officially classifying rigid sterilization containers with electronic monitoring as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change helps hospitals and medical device makers get these safer, smarter containers to patients faster and easier. The new rules took effect June 1, 2026, making it simpler and potentially less costly to bring these devices to market.
2026-10904 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Orally Ingested Transient Device for Constipation
The FDA is officially putting the new swallowed device for constipation into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this cool innovation by cutting down red tape. The new rules took effect June 1, 2026, and could save companies time and money getting their devices approved.
Previous / Next Documents
Previous: 2026-11045 — Submission for OMB Review; 30-Day Comment Request Regular Clearance for the National Institute of Mental Health Data Archive (NDA), (NIMH)
The National Institute of Mental Health (NIMH) is asking for a 30-day public comment period to review and approve their data collection process for the Mental Health Data Archive. This affects researchers and anyone who shares mental health data with NIMH. Comments are due by June 3, 2026, and there’s no new cost involved—just keeping things clear and up-to-date!
Next: 2026-11050 — Notice on Penalty Inflation Adjustments for Civil Monetary Penalties
The Social Security Administration is keeping civil monetary penalties (fines) at the same 2025 levels through January 14, 2027. This means anyone who might face these fines won’t see increases for now, even though they usually adjust for inflation every year. So, if you’re involved with Social Security rules, the penalty amounts won’t change for a while.